Allarity Therapeutics Announces Participation in Pharma Partnering Summit US
Registrants can request one-on-one meetings with Thomas Jensen, and more information about the summit can be found at the following link: https://pharma-partnering-summit.com/pps-wc.html
About Stenoparib
Stenoparib is an orally available, small-molecule dual-targeted inhibitor of PARP1/2 and tankyrase 1/2. At present, tankyrases are attracting significant attention as emerging therapeutic targets for cancer, principally due to their role in regulating the WNT signaling pathway. Aberrant Wnt/β-catenin signaling has been implicated in the development and progression of numerous cancers. By inhibiting PARP and blocking WNT pathway activation, stenoparib's unique therapeutic action shows potential as a promising therapeutic for many cancer types, including ovarian cancer. Allarity has secured exclusive global rights for the development and commercialization of stenoparib, which was originally developed by Eisai Co. Ltd. and was formerly known under the names E7449 and 2X-121.
About the Drug Response Predictor – DRP® Companion Diagnostic
Allarity uses its drug-specific DRP® to select those patients who, by the gene expression signature of their cancer, may have a high likelihood of benefiting from a specific drug. By screening patients before treatment, and only treating those patients with a sufficiently high, drug-specific DRP score, the therapeutic benefit rate may be enhanced. The DRP method builds on the comparison of sensitive vs. resistant human cancer cell lines, including transcriptomic information from cell lines, combined with clinical tumor biology filters and prior clinical trial outcomes. DRP is based on messenger RNA expression profiles from patient biopsies. The DRP® platform has shown an ability to provide a statistically significant prediction of the clinical outcome from drug treatment in cancer patients across dozens of clinical studies (both retrospective and prospective). The DRP platform, which may be useful in all cancer types and is patented for dozens of anti-cancer drugs, has been extensively published in the peer-reviewed literature.
About Allarity Therapeutics
Allarity Therapeutics, Inc. (NASDAQ: ALLR) is a clinical-stage biopharmaceutical company dedicated to developing personalized cancer treatments. The Company is focused on development of stenoparib, a novel PARP/tankyrase inhibitor for advanced ovarian cancer patients, using its DRP® technology to develop a companion diagnostic that can be used to select those patients expected to derive the greatest clinical benefit from stenoparib. Allarity is headquartered in the U.S., with a research facility in Denmark, and is committed to addressing significant unmet medical needs in cancer treatment. For more information, visit www.allarity.com.
Follow Allarity on Social Media
LinkedIn: https://www.linkedin.com/company/allaritytx/
Forward-Looking Statements
This press release contains 'forward-looking statements' within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements provide the Company's current expectations or forecasts of future events. The words 'anticipates,' 'believe,' 'continue,' 'could,' 'estimate,' 'expect,' 'intends,' 'may,' 'might,' 'plan,' 'possible,' 'potential,' 'predicts,' 'project,' 'should,' 'would' and similar expressions may identify forward-looking statements, but the absence of these words does not mean that a statement is not forward-looking. These forward-looking statements include, but are not limited to, corporate presentation highlighting Allarity's clinical strategy and development progress for stenoparib. Any forward-looking statements in this press release are based on management's current expectations of future events and are subject to multiple risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, statements concerning clinical development progress, trial design and enrollment for stenoparib, the potential benefits of DRP®-guided therapy, and efforts to achieve regulatory milestones. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled 'Risk Factors' in our Form 10-K annual report filed with the Securities and Exchange Commission (the 'SEC') on March 31, 2025, available at the SEC's website at www.sec.gov, and as well as discussions of potential risks, uncertainties and other important factors in the Company's subsequent filings with the SEC. All information in this press release is as of the date of the release, and the Company undertakes no duty to update this information unless required by law.
###
Company Contact:
[email protected]
Media Contact: Thomas Pedersen Carrotize PR & Communications +45 6062 9390
[email protected]
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
10 minutes ago
- Yahoo
Earnings Season Check-In: What to Watch Next With PayPal
Key Points PayPal reported earnings that beat on the top and bottom line. Transaction margin came in a little weaker than expected, sending the stock lower. The most exciting parts of PayPal's growth could be yet to come. 10 stocks we like better than PayPal › The second quarter's earnings season is winding down. And let's get it out of the way: PayPal (NASDAQ: PYPL) was not one of the top performers of earnings season. After the company reported its second-quarter results, the stock fell by about 8% the following day. Despite the stock performance, much of PayPal's results were strong, and the company beat expectations for both revenue and earnings per share (EPS). However, it's important for investors to keep in mind that PayPal's turnaround is still in its early stages, and there's a lot going on behind the scenes that isn't reflected in the numbers just yet. With that in mind, here's a rundown of how PayPal did in the second quarter, why the stock fell, and what investors should keep an eye on. The key numbers As mentioned, PayPal reported strong results on both the top and bottom lines. Revenue climbed by 5% year over year, and both revenue and earnings handily surpassed analysts' expectations. Total payment volume came in $10 billion higher than projected, and there are now 438 million active accounts. However, there was a lot that wasn't what investors were looking for, especially when it comes to profitability. One of the biggest areas of concern is maintaining transaction margins, and the growth rate of this metric declined sequentially. Plus, total operating expenses grew and free cash flow declined, missing expectations by a wide margin. Why investors shouldn't focus on these results To be sure, there were some disappointing figures in PayPal's second quarter earnings. But it would be a mistake to put too much emphasis on them. PayPal is a business that's in the middle of a turnaround. CEO Alex Chriss and his team spent much of 2024 focusing on efficiency, and it would be fair to call that a success. Now, PayPal is stepping on the gas when it comes to growth, rolling out many new initiatives and planning many more, but these aren't apparent in the numbers just yet. The company's new advertising platform is one example. It was launched in October 2024 but is still rather small. Monetization of Venmo is another big focus, and this one is actually starting to show up in the results. In fact, Venmo payment volume grew 12% year over year in the second quarter, while Venmo revenue grew 20%. That's a good indicator that the typical Venmo user is generating more income for the business. This could just be the beginning. Back in February, Chriss and his team laid out their long-term growth strategy in a 224-slide presentation (link opens a PDF). And just to name some of the highlights: PayPal ultimately wants to combine all of its platforms (PayPal, Venmo, Braintree, etc.) into one. The company sees a massive opportunity in offline (in-store) payments. This is a $200 billion market, of which PayPal has less than 1%. Scaling the omnichannel business is a major priority. PayPal plans to leverage its more than 500 petabytes of data from more than 430 million active accounts. One way it's doing that is through targeted advertising, but this is just one potential application. PayPal aims to utilize AI technology to boost engagement and add value to the platform. For example, AI can choose the credit card with the best rewards from a customer's wallet for a specific purchase. These are just a few examples, and I'd encourage you to look at the full presentation to get a complete picture of management's vision. In all, management believes PayPal can achieve an EPS growth rate in the "low teens" by 2027, and accelerate beyond that to a sustainable 20%-plus EPS growth rate in the long term. Given the results of the past few years, this seems like an ambitious goal, but with a current valuation of about 11 times free cash flow, the stock could be a massive win for investors if management can do it. Should you buy stock in PayPal right now? Before you buy stock in PayPal, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and PayPal wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Matt Frankel has positions in PayPal. The Motley Fool has positions in and recommends PayPal. The Motley Fool recommends the following options: long January 2027 $42.50 calls on PayPal and short September 2025 $77.50 calls on PayPal. The Motley Fool has a disclosure policy. Earnings Season Check-In: What to Watch Next With PayPal was originally published by The Motley Fool
Yahoo
10 minutes ago
- Yahoo
Morning Bid: Tech angst on AI doubts
By Mike Dolan LONDON (Reuters) - What matters in U.S. and global markets today By Mike Dolan, Editor-At-Large, Finance and Markets In markets, the trigger for sudden confidence swoons is often elusive, particularly when looking at periodic rotations out of high-flying U.S. tech stocks. And most signs suggest this week's tech retreat may be more about re-positioning than investors receiving some lightning bolt of news. Tuesday's tech shakeout led to a 1.5% plunge in the Nasdaq index even as the blue chip Dow Jones Industrials Average hit a record intraday high. But the tech slump dragged the S&P 500 down 0.6%, and U.S. equity futures showed little sign of a bounce early on Wednesday. * Reasons for the sudden tech angst tended to be gathered after the event, with some pointing to comments late last week from OpenAI boss Sam Altman on inevitable bubbles in the sector and others pointing to different research papers fretting variously about both the limited returns on blistering AI spending to date and also its growing jobs destruction. The jitters also come ahead of next week's earnings report from chip behemoth Nvidia, some concern about the wider implications of the U.S. government's proposed stake in ailing chip giant Intel and caution ahead of the Federal Reserve's annual Jackson Hole conference this week. * Even though Fed concerns were cited across markets on Tuesday, there was little shift in Fed futures pricing during the day - and they still show just over an 80% chance of a rate cut next month. With Fed meeting minutes due later today and 20-year bonds under the hammer too, Treasury yields were flat and the dollar firmer. An unexpected pick-up in housing starts in July was reported on Tuesday but this was offset by a drop in building permits to five-year lows. * Tech-heavy stock indexes overseas were hit by Wall Street's wobble, with Japan's Nikkei losing 1.5% and South Korea's Kospi down 0.7%. Lifted on Tuesday by Ukraine deal hopes, European stocks were flatter today, with euro inflation coming in bang on forecast and a hotter-than-expected UK inflation reading downplayed due to seasonal airfare skews. Chinese stocks outperformed, with the Shanghai main index rallying to 10-year highs, as investors rotated stock holdings and hoped for more government stimulus. Be sure to check out today's column, which looks at a particular dilemma facing the Fed: should it ease to offset weakness in the housing market if that means spurring the blistering AI infrastructure boom? Today's Market Minute * U.S. and European military planners have begun exploring post-conflict security guarantees for Ukraine, U.S. officials and sources told Reuters on Tuesday, following President Donald Trump's pledge to help protect the country under any deal to end Russia's war. * Alongside a massive build-up in conventional military firepower, China has embarked on a rapid and sustained increase in the size and capability of its nuclear forces, according to the U.S. military and arms control experts. * British inflation hit its highest in 18 months in July when it increased to 3.8% from 3.6% in June, official data showed on Wednesday, once again leaving the country with the biggest price growth problem amongst the world's big rich economies. * A glaring mismatch between benchmark oil prices and expectations of a looming supply overhang has created an imbalance that could end badly for traders, writes ROI energy columnist Ron Bousso. * Trump has faced little opposition in his drive to rip up the global economic rule book. The only exception has been "the market". But now even investors are holding their fire, claims ROI markets columnist Jamie McGeever, enabling more risk to build up in the financial system. Chart of the day Americans are deeply concerned over the prospect that advances in artificial intelligence could put swaths of the country out of work permanently, according to a new Reuters/Ipsos poll. The six-day poll, which concluded on Monday, showed 71% of respondents said they were concerned that AI will be "putting too many people out of work permanently." Today's events to watch * Federal Reserve meeting minutes released (2:00 PM EDT); Board Governor Christopher Waller and Atlanta Fed President Raphael Bostic speak * U.S. corporate earnings: Target, Nordson, TJX, Lowe's, Estee Lauder, Progressive, Analog Devices * U.S. Treasury sells $16 billion of 20-year bonds Want to receive the Morning Bid in your inbox every weekday morning? Sign up for the newsletter here. You can find ROI on the Reuters website, and you can follow us on LinkedIn and X. Opinions expressed are those of the author. They do not reflect the views of Reuters News, which, under the Trust Principles, is committed to integrity, independence, and freedom from bias. (By Mike Dolan; Editing by Aidan Lewis) Melden Sie sich an, um Ihr Portfolio aufzurufen.
Yahoo
10 minutes ago
- Yahoo
If You'd Invested $1,000 in Tilray Stock 5 Years Ago, Here's How Much You'd Have Today
Key Points Tilray Brands has faced significant challenges over the past five years. The company's shares have substantially lagged the market. There is little hope for a comeback for the stock. 10 stocks we like better than Tilray Brands › The cannabis industry experienced significant regulatory progress toward the end of the last decade, arguably none more important than Canada's legalization of recreational uses of the substance in 2018. This move attracted the attention of investors who rushed to purchase shares of notable cannabis companies, including Tilray Brands (NASDAQ: TLRY). The company quickly established itself as a leader in the industry, a position it has maintained since. However, this hasn't exactly translated to strong stock market performances. Read on to find out how you would have fared if you had put $1,000 in Tilray five years ago. You wouldn't have much money left Let's go through some of the issues Tilray and its peers have faced over the past five years. First, seeing a massive opportunity to dominate a newly legalized market in Canada, cannabis companies started popping up like weeds. That created significant competition for market share. Second, even though recreational uses of marijuana were now legal in Canada, there were still stringent regulations regarding the production, sale, and distribution of the substance. For instance, retailers needed to obtain the appropriate license to stay on the right side of the law, among other things. However, different provinces in Canada had slightly different rules. In the most populous province, Ontario, which accounts for almost 40% of the Canadian population, a complex lottery system was initially used to grant licenses to retailers. As the former CEO of Canopy, Mark Zekulin, famously said in 2019, "The market opportunity today is simply not living up to expectations and ... the inability of the Ontario government to license retail stores right off the bat has resulted in half of the expected market in Canada simply not existing." Third, illegal routes to obtain cannabis haven't disappeared in Canada despite legalization. According to some reports, as of 2022, 33% of the marijuana market in Canada was from illicit channels. Tilray had to contend with oversupply and competition from illegal retailers, which helped push down prices, while also facing a smaller overall market due to complex licensing requirements. The company's financial results have been inconsistent at best over the past five years, and the stock has been on a downward spiral. So, if you had invested $1,000 in Tilray five years ago, you'd have about $163 left as of this writing. By comparison, $1,000 invested in the S&P 500 five years ago would be worth $2,067 today. Cut your losses while there is still time Those who are bullish on the stock would point to several developments that could allow Tilray to bounce back. First, the company has diversified its operations across cannabis, wellness (including hemp-based food products), the purchase and resale of certain pharmaceuticals, and a craft brewing business. Second, Tilray is still counting on legalization in the U.S. The recent news that President Donald Trump might consider rescheduling cannabis from a Schedule I to a Schedule III substance jolted the stock. However, none of these are compelling enough arguments to justify sticking with Tilray. The company's diversified operations have not enabled it to generate consistent financial results over the past few years. Tilray remains unprofitable. Moreover, even assuming Tilray gets something better than rescheduling and cannabis is legalized in the U.S. at the federal level, that's no guarantee of success. It will depend on a range of factors that are beyond the company's control. For instance, what will the rules regarding the sale and distribution of cannabis-based products look like? Besides the Canadian experience, it's worth noting that Germany legalized recreational cannabis for adults last year, which has not led to a market opportunity. Among other reasons, there are no cannabis stores and no one is allowed to sell the substance. Instead, people have to grow marijuana at home (limited amounts of it) or join a cannabis club to obtain it. No one can join more than one club, and clubs are restricted to 500 members. Will legalization in the U.S. look like that? It's hard to say, but without knowing the specifics -- which no one does, since we aren't even sure it will happen -- there is no telling how Tilray will fare. Even if the rules create a significant market opportunity, larger companies with deeper pockets and extensive experience in dealing with highly regulated substances may enter and dominate the market. What's the verdict? Tilray's performance over the next five years will look much like the past five, in my view. The stock still isn't worth investing in. Should you invest $1,000 in Tilray Brands right now? Before you buy stock in Tilray Brands, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Tilray Brands wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $671,466!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,115,633!* Now, it's worth noting Stock Advisor's total average return is 1,077% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 18, 2025 Prosper Junior Bakiny has no position in any of the stocks mentioned. The Motley Fool recommends Tilray Brands. The Motley Fool has a disclosure policy. If You'd Invested $1,000 in Tilray Stock 5 Years Ago, Here's How Much You'd Have Today was originally published by The Motley Fool Sign in to access your portfolio
